Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

3D engineered heart tissue for replacement therapy.

Thomas Eschenhagen1, Michael Didié, Felix Münzel

  • 1Department of Clinical Pharmacology and Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuremberg, Fahrstrasse 17, 91054 Erlangen, Germany. thomas.eschenhagen@pharmakologie.uni-erlangen.de

Basic Research in Cardiology
|December 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human induced pluripotent stem cell cardiomyocytes for risk stratification of patients with LQT syndrome - ready for practice?

Cardiovascular research·2026
Same author

Mechanical load inhibits cancer growth in mouse and human hearts.

Science (New York, N.Y.)·2026
Same author

Models of the human heart for biomedical research: Opportunities and challenges.

Physiological reports·2026
Same author

Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in <i>LMNA</i> Mutation-Induced Dilated Cardiomyopathy.

Circulation. Heart failure·2026
Same author

Activation of IRF3 in cardiomyocytes impairs mitochondrial oxidative function through PGC-1α inhibition and drives heart failure.

Nature communications·2026
Same author

Higher sensitivity to ouabain-induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes than human adult heart tissue despite similar Na<sup>+</sup>/K<sup>+</sup>-ATPase pump current amplitudes.

British journal of pharmacology·2026

Engineered heart tissues (EHTs) offer a promising solution for repairing hearts damaged by myocardial infarction. These preformed tissues, unlike isolated cells, show feasibility for in vivo tissue replacement.

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Biology
  • Biomedical Engineering

Background:

  • Myocardial infarction causes irreversible cardiac myocyte loss, leading to heart failure.
  • Current cell or tissue grafting methods face challenges with myocyte integration and functional improvement.
  • Engineered heart tissues (EHTs) offer a potential solution by providing preformed, functional cardiac tissue constructs.

Purpose of the Study:

  • To evaluate the feasibility of using three-dimensional engineered heart tissues (EHTs) as graft material for in vivo cardiac repair.
  • To assess the survival, integration, and vascularization of EHTs when implanted into a host environment.
  • To determine if EHTs offer advantages over single-cell grafting for myocardial repair.

Main Methods:

  • Generation of three-dimensional engineered heart tissues (EHTs) in vitro using embryonic chick or neonatal rat cardiac myocytes.

Related Experiment Videos

  • Implantation of EHTs into the peritoneum of Fisher 344 rats to assess in vivo performance.
  • Evaluation of EHT survival, myocyte network maintenance, and vascularization at 14 days post-implantation.

    • Main Results:

    • Implanted EHTs survived for at least 14 days in the peritoneal environment.
    • The EHTs maintained their differentiated cardiac myocyte network.
    • Strong vascularization of the implanted EHTs was observed, indicating successful integration with host vasculature.

    Conclusions:

    • Engineered heart tissues (EHTs) demonstrate feasibility as a novel biomaterial for cardiac tissue repair.
    • Preformed EHTs represent a promising alternative to isolated cell transplantation for myocardial regeneration.
    • This study provides initial evidence supporting EHTs for future tissue replacement strategies in cardiovascular medicine.